We are analyzing https://link.springer.com/article/10.1007/s11912-020-0887-y.

Title:
Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer | Current Oncology Reports
Description:
Purpose of Review Small cell lung cancer (SCLC) is an exceptionally lethal subtype of lung cancer. For patients with extensive-stage (ES) disease, which is the majority of patients, platinum-doublet chemotherapy has been the standard of care for decades. Dozens of phase III trials have failed to improve survival over standard platinum plus etoposide. Recent results, however, have met with long-overdue success. This manuscript reviews the new standards of care for ES-SCLC. Recent Findings Two recent phase III trials have shown an improvement in overall survival with concurrent immunotherapy and chemotherapy. In IMpower 133, the addition of the anti-PD-L1 antibody atezolizumab to carboplatin plus etoposide significantly improved both progression-free survival (PFS) and overall survival (OS). This was the first trial in over 30 years to improve survival. In CASPIAN, concurrent durvalumab, another anti-PD-L1 antibody, also led to an improvement in survival. Summary While there is clearly a need to further improve outcomes, the improvement in survival with the addition of atezolizumab or durvalumab to platinum-doublet chemotherapy is a major advance. We now have new standards of care and the potential of a more meaningful benefit for patients with advanced SCLC.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cancer, lung, article, pubmed, google, scholar, cas, smallcell, phase, oncol, iii, trial, clin, extensivestage, randomized, chemotherapy, etoposide, study, httpsdoiorgjco, patients, firstline, treatment, cell, small, cisplatin, survival, results, versus, liu, sclc, oncology, central, carboplatin, multicenter, extensive, group, research, durvalumab, ann, atezolizumab, therapy, clinical, ipilimumab, content, trials, improve, access, privacy, cookies, armstrong,

Topics {✒️}

extensive-disease-small-cell lung cancer granulocyte colony-stimulating factor small-cell lung cancer small-cell lung cancer anti-pd-l1 antibody atezolizumab month download article/chapter belotecan/cisplatin versus etoposide/cisplatin amrubicin/cisplatin versus etoposide/cisplatin anti-pd-l1 antibody goirc-aifa farm6pmfjm trial current cancer research anti-pd-l1 antibodies lung cancer access extensive-stage sclc previously untreated patients progression-free survival springer international publishing phase iii trials full article pdf phase iii trial clin lung cancer standard versus alternating extensive-stage extensive disease phase iii study southwest oncology group randomized controlled trial privacy choices/manage cookies doxorubicin-based chemotherapy compared maintenance immunotherapy study shepherd fa cisplatin versus alternation natl cancer inst national cancer institute piha-paul sa pd-l1 expression lung cancer received research funding dashing decades phase ii study additional information publisher topotecan versus observation single-agent amrubicin standard-dose etoposide cisplatin-based chemotherapy de braud fg important negative result article armstrong randomized trials multicenter retrospective analysis

Questions {❓}

Is there a case for cisplatin in the treatment of small-cell lung cancer?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer
         description:Small cell lung cancer (SCLC) is an exceptionally lethal subtype of lung cancer. For patients with extensive-stage (ES) disease, which is the majority of patients, platinum-doublet chemotherapy has been the standard of care for decades. Dozens of phase III trials have failed to improve survival over standard platinum plus etoposide. Recent results, however, have met with long-overdue success. This manuscript reviews the new standards of care for ES-SCLC. Two recent phase III trials have shown an improvement in overall survival with concurrent immunotherapy and chemotherapy. In IMpower 133, the addition of the anti-PD-L1 antibody atezolizumab to carboplatin plus etoposide significantly improved both progression-free survival (PFS) and overall survival (OS). This was the first trial in over 30 years to improve survival. In CASPIAN, concurrent durvalumab, another anti-PD-L1 antibody, also led to an improvement in survival. While there is clearly a need to further improve outcomes, the improvement in survival with the addition of atezolizumab or durvalumab to platinum-doublet chemotherapy is a major advance. We now have new standards of care and the potential of a more meaningful benefit for patients with advanced SCLC.
         datePublished:2020-02-07T00:00:00Z
         dateModified:2020-02-07T00:00:00Z
         pageStart:1
         pageEnd:9
         sameAs:https://doi.org/10.1007/s11912-020-0887-y
         keywords:
            Small cell lung cancer
            SCLC
            Extensive-stage
            Clinical trials
            Immunotherapy
            Atezolizumab
            Durvalumab
            Oncology
         image:
         isPartOf:
            name:Current Oncology Reports
            issn:
               1534-6269
               1523-3790
            volumeNumber:22
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Samantha A. Armstrong
               affiliation:
                     name:Georgetown University
                     address:
                        name:Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stephen V. Liu
               affiliation:
                     name:Georgetown University
                     address:
                        name:Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer
      description:Small cell lung cancer (SCLC) is an exceptionally lethal subtype of lung cancer. For patients with extensive-stage (ES) disease, which is the majority of patients, platinum-doublet chemotherapy has been the standard of care for decades. Dozens of phase III trials have failed to improve survival over standard platinum plus etoposide. Recent results, however, have met with long-overdue success. This manuscript reviews the new standards of care for ES-SCLC. Two recent phase III trials have shown an improvement in overall survival with concurrent immunotherapy and chemotherapy. In IMpower 133, the addition of the anti-PD-L1 antibody atezolizumab to carboplatin plus etoposide significantly improved both progression-free survival (PFS) and overall survival (OS). This was the first trial in over 30 years to improve survival. In CASPIAN, concurrent durvalumab, another anti-PD-L1 antibody, also led to an improvement in survival. While there is clearly a need to further improve outcomes, the improvement in survival with the addition of atezolizumab or durvalumab to platinum-doublet chemotherapy is a major advance. We now have new standards of care and the potential of a more meaningful benefit for patients with advanced SCLC.
      datePublished:2020-02-07T00:00:00Z
      dateModified:2020-02-07T00:00:00Z
      pageStart:1
      pageEnd:9
      sameAs:https://doi.org/10.1007/s11912-020-0887-y
      keywords:
         Small cell lung cancer
         SCLC
         Extensive-stage
         Clinical trials
         Immunotherapy
         Atezolizumab
         Durvalumab
         Oncology
      image:
      isPartOf:
         name:Current Oncology Reports
         issn:
            1534-6269
            1523-3790
         volumeNumber:22
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Samantha A. Armstrong
            affiliation:
                  name:Georgetown University
                  address:
                     name:Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stephen V. Liu
            affiliation:
                  name:Georgetown University
                  address:
                     name:Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Oncology Reports
      issn:
         1534-6269
         1523-3790
      volumeNumber:22
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Georgetown University
      address:
         name:Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
         type:PostalAddress
      name:Georgetown University
      address:
         name:Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Samantha A. Armstrong
      affiliation:
            name:Georgetown University
            address:
               name:Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
               type:PostalAddress
            type:Organization
      name:Stephen V. Liu
      affiliation:
            name:Georgetown University
            address:
               name:Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
      name:Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(224)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.74s.

LINK . SPRINGER . COM {}